CGTX
Cognition Therapeutics, Inc. NASDAQ Listed Oct 8, 2021$1.16
Mkt Cap $85.4M
52w Low $0.22
26.0% of range
52w High $3.83
50d MA $1.07
200d MA $1.41
P/E (TTM)
-4.0x
EV/EBITDA
-1.3x
P/B
2.7x
Debt/Equity
0.0x
ROE
-68.5%
P/FCF
-4.0x
RSI (14)
—
ATR (14)
—
Beta
1.40
50d MA
$1.07
200d MA
$1.41
Avg Volume
1.1M
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CIK (SEC)
Phone
412 481 2210
2500 Westchester Avenue · Purchase, NY 10577 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.06 | -0.02 | +66.7% | 1.08 | -0.9% | -32.4% | -18.6% | +27.7% | +17.4% | -2.6% | — |
| Nov 6, 2025 | AMC | -0.07 | -0.06 | +14.3% | 1.66 | +0.0% | +0.0% | +1.2% | +4.2% | -1.7% | -10.5% | — |
| Aug 7, 2025 | AMC | -0.12 | -0.11 | +8.3% | 0.68 | -0.2% | +11.4% | +13.8% | +28.1% | +10.9% | +36.1% | — |
| May 7, 2025 | AMC | -0.12 | -0.14 | -16.7% | 0.35 | -1.3% | -7.0% | -8.8% | +8.6% | -1.7% | +3.8% | — |
| Mar 20, 2025 | AMC | -0.16 | -0.17 | -6.2% | 0.43 | -1.6% | +6.6% | +7.7% | -6.2% | -3.9% | +2.1% | — |
| Nov 13, 2024 | AMC | -0.24 | -0.25 | -4.2% | 0.54 | -1.3% | -4.7% | -9.9% | +0.3% | -4.0% | -0.9% | — |
| Aug 8, 2024 | AMC | -0.22 | -0.18 | +18.2% | 0.58 | +2.2% | -6.4% | +3.9% | +3.8% | +4.4% | +4.3% | — |
| May 7, 2024 | AMC | -0.23 | -0.27 | -17.4% | 1.92 | +1.6% | +4.2% | -4.5% | +1.6% | +0.5% | +1.5% | — |
| Mar 26, 2024 | AMC | -0.38 | -0.27 | +28.9% | 1.83 | +2.7% | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% | — |
| Nov 2, 2023 | AMC | -0.31 | -0.22 | +29.0% | 1.02 | +3.9% | +3.9% | +0.0% | -1.9% | +9.6% | -12.3% | — |
| Aug 8, 2023 | AMC | -0.25 | -0.16 | +36.0% | 1.72 | +3.5% | +0.0% | -2.3% | -4.8% | -4.4% | -2.6% | — |
| May 4, 2023 | AMC | -0.17 | -0.21 | -23.5% | 1.67 | +1.8% | -6.6% | +3.2% | +0.0% | -2.5% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $1.08 | $1.07 | -0.9% | -32.4% | -18.6% | +27.7% | +17.4% | -2.6% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | -2.2% | -1.7% | +1.2% | -4.0% | +0.6% |
| Nov 21 | B. Riley Securities | Maintains | Buy → Buy | — | $1.33 | $1.36 | +2.3% | +4.5% | +10.1% | -4.6% | +13.0% | +5.5% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.51 | -0.7% | -8.6% | -4.3% | +4.5% | +10.1% | -4.6% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $0.68 | $0.68 | -0.2% | +11.4% | +13.8% | +28.1% | +10.9% | +36.1% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.30 | $0.31 | +3.6% | +8.2% | -7.6% | +3.3% | +0.8% | +7.3% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.30 | $0.30 | +0.5% | -12.9% | -5.8% | +2.1% | -3.9% | +32.6% |
| May 8 | Chardan Capital | Maintains | Buy → Buy | — | $0.35 | $0.35 | -1.3% | -7.0% | -8.8% | +8.6% | -1.7% | +3.8% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.45 | $0.45 | -1.1% | +7.7% | -6.2% | -3.9% | +2.1% | -7.8% |
| Mar 21 | Chardan Capital | Maintains | Buy → Buy | — | $0.43 | $0.42 | -1.6% | +6.6% | +7.7% | -6.2% | -3.9% | +2.1% |
| Feb 26 | Chardan Capital | Maintains | Buy → Buy | — | $0.52 | $0.50 | -2.6% | -4.2% | -7.4% | -0.7% | -5.4% | -2.3% |
| Dec 19 | Chardan Capital | Maintains | Buy → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Dec 19 | B. Riley Securities | Upgrade | Neutral → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.40 | $0.41 | +0.1% | -1.6% | +1.0% | -0.5% | -3.3% | -1.8% |
| Nov 15 | Chardan Capital | Maintains | Buy → Buy | — | $0.51 | $0.50 | -2.3% | -9.9% | +0.3% | -4.0% | -0.9% | -0.0% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.47 | $0.47 | +0.0% | +0.7% | +2.9% | +2.4% | +4.1% | -2.9% |
| Oct 31 | Chardan Capital | Maintains | Buy → Buy | — | $0.53 | $0.52 | -2.1% | -11.1% | -0.3% | +0.7% | +2.9% | +2.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.8% | +3.9% | +3.8% | +4.4% | +4.3% | +10.6% |
| Aug 6 | B. Riley Securities | Downgrade | Buy → Neutral | — | $0.66 | $0.66 | +0.0% | -1.7% | -9.8% | +0.5% | -6.4% | +3.9% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.00 | $0.97 | -3.0% | -10.0% | -19.0% | -10.0% | -1.7% | -9.8% |
| Jul 30 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $1.33 | $1.10 | -17.3% | -17.3% | -9.1% | -10.0% | -19.0% | -10.0% |
| Jul 2 | Rodman & Renshaw | Maintains | Buy → Buy | — | $1.67 | $1.75 | +4.8% | +9.0% | -2.7% | +7.9% | -1.6% | +9.6% |
| Mar 28 | B. Riley Securities | Maintains | Buy → Buy | — | $1.82 | $1.81 | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% | -2.0% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.83 | $1.88 | +2.7% | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% |
| Aug 14 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $1.60 | $1.61 | +0.6% | -4.4% | -2.6% | +3.4% | -1.3% | +0.7% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.61 | $1.63 | +1.2% | +0.0% | -2.5% | +1.3% | +0.6% | +6.9% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.83 | $1.79 | -2.2% | +6.0% | +7.7% | -2.4% | -2.5% | -2.5% |
| Sep 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.74 | $1.89 | +8.6% | +13.8% | -4.0% | -4.7% | +6.1% | +3.1% |
| Apr 22 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3.10 | $3.34 | +7.7% | +1.6% | -3.2% | -7.5% | +2.8% | -0.7% |
| Nov 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.21 | $12.71 | +4.1% | +2.6% | -1.0% | -3.1% | +0.9% | +7.0% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CGTX issued a press release on March 26, 2026, signaling potential material news that investors should review immediately, as 8-K filings typically disclose significant corporate developments affecting stock valuation.
Mar 26
8-K · 8.01
!! High
Cognition Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cognition Therapeutics filed a material event announcement via press release, though the specific details require reviewing the attached exhibit to understand the announcement's impact on investors.
Mar 2
Data updated apr 25, 2026 1:02am
· Source: massive.com